Skip to main content

Want a detailed portfolio tracker?

Insight Molecular Diagnostics (IMDX) P/E (2016 - 2026)

Insight Molecular Diagnostics (IMDX) P/E from Jan 4, 2016 to Jul 21, 2026. The TTM Insight Molecular Diagnostics (IMDX) P/E is -3.03. You can export chart.

All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.

P/E

Annual P/E change of Insight Molecular Diagnostics (IMDX)

YearP/EChange
2026-3.03-29.28%
2025-4.28+685.89%
2024-0.54+93.20%
2023-0.28-42.98%
2022-0.49-84.08%
2021-3.10-41.37%
2020-5.30-1.72%
2019-5.39+55.32%
2018-3.47-54.01%
2017-7.54-52.41%
2016-15.85N/A

Comparison Insight Molecular Diagnostics (IMDX) P/E with competitors

Insight Molecular Diagnostics (IMDX) P/E is -3.03.

TickerNameP/EUpside
ADVBAdvanced Biomed Inc1.05-134.65%
MBAICheckCap Ltd1.71-156.60%
FONRFonar Corp15.48-611.52%
QGENQiagen NV20.03-761.94%
DGXQuest Diagnostics Inc22.47-842.69%
LHLaboratory Corp Of America Holdings23.87-888.88%
IQVIQVIA Holdings Inc25.28-935.54%
AAgilent Technologies Inc26.96-990.90%
TMOThermo Fisher Scientific Inc31.53-1141.96%
MTDMettler-Toledo International Inc32.45-1172.41%
MEDPMedpace Holdings Inc32.55-1175.70%
DHRDanaher Corp38.55-1374.10%
IDXXIdexx Laboratories Inc40.58-1440.92%
RVTYRevvity Inc52.68-1840.98%
VCYTVeracyte Inc53.71-1875.05%
ICLRIcon Plc57.45-1998.63%
SHCSotera Health Company74.08-2548.31%
WATWaters Corp102.79-3496.83%